semaglutide weight loss clinic in new haven ct Program CT Medical Weight Loss &

A large observational study confirms previous clinical data on semaglutide lowering the risk of heart attack, stroke, death and separate hospitalization for heart failure.

GLP-1 and its synthetic analogs have emerged as significant therapeutic agents for the management of metabolic disorders, merging glycemic control with weight loss through innovative structural and delivery breakthroughs

Glucagon-like peptide-1 agonists (GLP-1s) have been in the spotlight as demand has grown to support type 2 diabetes and weight loss

Federal officials say a preliminary review finds no connection between suicidal thoughts and a new class of diabetes and obesity drugs